Contracts signed with Jean-Pierre Trudel & Associates and
Mentus Life Science
Ticker Symbol: CUR
QUEBEC CITY, Nov. 13 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests and
delivering lab services, today announced that it has retained the services of
Jean-Pierre Trudel & Associates, from Montreal (Canada), and Mentus Life
Science, from San Diego (US), for its public and investor relations
"Communicating with our shareholders, analysts and other supporters is
important to us," explained John Schafer, CEO and President of DiagnoCure. "In
2007, we initiated the implementation of a new strategic business plan and
acquired five promising gene-based diagnostic tests for cancer. We are
currently establishing our new service laboratory in the United States, and
intend to launch our first colorectal cancer test in 2008 through that lab.
With the experience of Jean-Pierre Trudel and Mentus, our investors will be
kept well informed about our progress."
Jean-Pierre Trudel & Associates specializes in the biotechnology sector
and has advised and supported several companies in their communication efforts
over the past 10 years. The team cumulates over 30 years of experience in
public and investor relations, including several years in journalism and in
large high-tech and pharma companies.
Mentus Life Science is an integrated communications and marketing agency,
with over 26 years of experience specializing in the life sciences industry.
The agency uses strategic branding, marketing, public relations, and investor
communication programs to successfully launch products and establish companies
in their markets.
DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering lab services that increase
clinician and patient confidence in making critical treatment decisions.
DiagnoCure is currently preparing to launch the first GC-C-based molecular
test for the management of colorectal cancer. In 2003, the Company entered
into a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development
and commercialization of a second-generation test for PCA3, DiagnoCure's
proprietary genetic marker highly specific to prostate cancer. The test is now
available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA(TM)
PCA3 in vitro assay. In addition to its own research, the Company intends to
acquire or in-license additional promising cancer biomarkers from both
academic and commercial institutions. For more information visit
This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
For further information:
For further information: Jean-Pierre Trudel & Associates: Jean-Pierre
Trudel, (514) 347-6111, email@example.com; DiagnoCure Inc.: (418)